Clinical trial

A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

Opening soon · Phase 1 · 1 countries · Registry ID NCT07748351

Opening soonPhase 1Interventional

What this study is about

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) and formulation (version) of the study medicine that can be used in future studies. The goals of this study are to learn about: The safety of different formulations of MK-4082 and if people tolerate them What happens to different formulations of MK-4082 in a person's body over time

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 60 Years

SexAll

Healthy volunteersAccepted

ConditionHealthy

Full registry criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) between 25 and 40 kg/m\^2, inclusive and weighs at least 60 kg Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss * Has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2

Treatments and study arms

MK-4082 Formulation 1 (F1)

Drug

Oral Tablet

MK-4082 Formulation 2 (F2)

Drug

Oral Tablet

MK-4082 Formulation 4 (F4)

Drug

Oral Tablet

Primary outcomes

Number of Participants Who Experience an Adverse Event (AE)Up to approximately 8 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

Number of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 6 weeks

Study locations

1 locations were listed when this page was built. The first 40 are shown.

ProSciento Inc. ( Site 0002)🇺🇸 Chula Vista, California, United States

Open map

Study CoordinatorContact

Call 619-427-1300